OncRef

Clinical Trial: NCT01684397

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Roswell Park Cancer Institute
Information Provided By:Roswell Park Cancer Institute
Last Update Posted:2026-11-05

Study Overview

Brief Summary

This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.

Official Title

A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients

Conditions

Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer

Intervention / Treatment

  • Biological: Bevacizumab
  • Other: Laboratory Biomarker Analysis
  • Drug: Pazopanib Hydrochloride
  • Other: Pharmacological Study

Other Study ID Numbers

  • I 191711
  • NCI-2012-01247
  • 13-069
  • I 191711

Start Date (Actual)

2012-11-21

Primary Completion Date (Estimated)

2027-02-20

Study Completion Date (Estimated)

2027-02-20

Enrollment (Actual)

51

Study Type

Interventional

Phase

Phase 1, Phase 2